Compare Amylx Pharmaceuticals Inc (AMLX) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Estee Lauder Companies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Estee Lauder Companies Inc trades at $83.5 (market cap $29.91B). The key difference: Estee Lauder Companies Inc is far larger — about 15.1× Amylx Pharmaceuticals Inc's market cap, and Estee Lauder Companies Inc pays a 1.69% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EL | |
|---|---|---|
Market Cap | $1.98B | $29.91B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $119.61 |
52-Week Low | $7.64 | $67.23 |
Enterprise Value | $1.70B | $36.08B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Estée Lauder (EL) trades at $82.66, up 0.82% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported negative net income of -$1.13B in 2025, though it has beaten EPS estimates in recent quarters. Revenue has declined from $17.7B in 2022 to $14.33B in 2025, while debt-to-asset ratio rose to 36.78%.
The outlook is mixed: analyst consensus is a Buy with a $90.60 price target, but high valuation ratios and profitability challenges pose risks. Positive sentiment from news highlights innovation and industry trends, yet financial performance and macroeconomic pressures remain headwinds for near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
